Indaptus Therapeutics, Inc. (INDP) is a New York-based, pre-revenue biotechnology company built around its patented Decoy platform, which uses attenuated, killed non-pathogenic Gram-negative bacteria designed to activate innate and adaptive immunity. The company has wound down clinical activity for its lead candidate Decoy20 and is now pursuing a strategic review alongside early-stage research into a potential neurotechnology and neural-network-based device for sleep-related conditions.
Shares rose 8.52% to $3.44 in Monday trading, up from Friday's close of $3.17 — a gain of $0.27. The direction was unambiguously higher, driven by delayed buying interest in the third-quarter report and corporate update issued after Friday's close, which gave the market its first uninterrupted session to price the news.
Indaptus disclosed third-quarter results after the bell on Friday, and the initial after-hours response was muted, with the stock quoted up less than 2%. Monday's session told a different story. Buyers pushed the shares from a flat open to $3.55 before midday, a pattern consistent with retail and momentum accounts digesting the release during regular hours rather than in thin evening quotes.
The numbers themselves were modest but constructive. The quarterly net loss narrowed to approximately $1.05 million from roughly $2.98 million a year earlier, breakeven on a per-share basis at a loss of $0.01. Research and development expense fell 82% to about $0.27 million, and general and administrative costs declined 24%. Total liquidity of roughly $30.6 million, including certificates of deposit redeemable on demand plus the remaining proceeds of a September private placement, gives management an unusually long runway for a company of this size.
The more speculative driver was the wording of the corporate update. Indaptus said it continues to evaluate the Decoy platform and existing therapeutic assets for licensing, partnership and other strategic opportunities, and repeated that it is considering investments in or acquisitions of operating businesses. It also described early-stage, preclinical evaluation of a sleep-focused neurotechnology device, with the stated ambition of exploring a possible development pathway toward a future FDA submission.
That combination — a funded shell with a strategic-review mandate — is precisely what has driven this stock's extraordinary 2026 run from under $1 in August to above $3.50. Today's move extends that narrative without introducing a new, concrete transaction.
The advance stood out because the backdrop was decisively negative. The S&P 500 fell about 2.0%, the Nasdaq-100 proxy QQQ dropped roughly 2.65%, and biotech benchmarks were weaker still, with the XBI down 2.7% and the IBB off 1.8%. A micro-cap rallying more than 8% into that tape signals stock-specific demand rather than sector sympathy.
Volume was elevated relative to the quiet recent baseline — roughly 300,000 shares by mid-afternoon against a 20-day average near 239,000 — but dwarfed by the millions of shares that traded in September. The float remains small at about 45 million shares with insider ownership near 70%, which amplifies price swings. The stock is holding above its 50-day average near $2.96 and its 200-day average near $2.32, and RSI has moved from neutral territory toward the low 60s.
The scoring scale runs from 0, meaning no meaningful news and a price move that is normal for the stock, to 100, meaning transformative news and an extreme, rare move. Indaptus scores 25 out of 100.
The verified news was a routine quarterly report for a pre-revenue company: no revenue, no active clinical programs, and cost reductions that were partly telegraphed in prior quarters. It was constructive but not material relative to a market capitalization near $460 million. The price move was equally unremarkable by this stock's standards — 8.52% is roughly in line with the typical absolute daily move of about 8.6%, and 19 of the last 60 sessions produced moves of equal or larger size. With both components weak, the two combine into a low score.
Indaptus has no scheduled earnings release until its fourth-quarter and full-year 2026 report, expected in the first quarter of 2027, so the near-term calendar is driven by corporate announcements rather than financial reporting. Investors will focus on whether the strategic review produces a concrete licensing deal, partnership, or acquisition, and on any further detail about the sleep-device research program.
The principal risk is dilution: 153.6 million shares are now outstanding following the October 16 closing of the September placement, and the company has repeatedly acknowledged the need for additional capital. Nasdaq continued-listing requirements and the absence of an active clinical program remain structural overhangs. Analyst coverage is thin, with a single firm carrying a buy rating. Sentiment in the broader small-cap biotech complex, which weakened again today, will likely determine whether this divergence holds.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the featured lineup rotates as conditions change. For investors navigating volatile micro-caps like this one, reviewing the current leaders can help frame how automated strategies are positioning right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Stochastic Oscillator for INDP moved out of overbought territory on November 19, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 41 similar instances where the indicator exited the overbought zone. In 38 of the 41 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INDP as a result. In 87 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for INDP turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 44 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INDP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The 50-day moving average for INDP moved above the 200-day moving average on October 22, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +9.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where INDP advanced for three days, in 170 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
INDP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 66 of 90 cases where INDP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. INDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (38.898) is normal, around the industry mean (3.596). P/E Ratio (-0.933) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INDP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology